73 related articles for article (PubMed ID: 21749165)
1. Targeting HIV entry through interaction with envelope glycoprotein 120 (gp120): synthesis and antiviral evaluation of 1,3,5-triazines with aromatic amino acids.
Lozano V; Aguado L; Hoorelbeke B; Renders M; Camarasa MJ; Schols D; Balzarini J; San-Félix A; Pérez-Pérez MJ
J Med Chem; 2011 Aug; 54(15):5335-48. PubMed ID: 21749165
[TBL] [Abstract][Full Text] [Related]
2. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
Kazmierski WM; Kenakin TP; Gudmundsson KS
Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV entry by carbohydrate-binding proteins.
Balzarini J
Antiviral Res; 2006 Sep; 71(2-3):237-47. PubMed ID: 16569440
[TBL] [Abstract][Full Text] [Related]
4. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells.
Xiao X; Kinter A; Broder CC; Dimitrov DS
Exp Mol Pathol; 2000 Jun; 68(3):133-8. PubMed ID: 10816381
[TBL] [Abstract][Full Text] [Related]
5. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
[TBL] [Abstract][Full Text] [Related]
6. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
7. A combination of molecular dynamics and docking calculations to explore the binding mode of ADS-J1, a polyanionic compound endowed with anti-HIV-1 activity.
Manetti F; Tintori C; Armand-Ugón M; Clotet-Codina I; Massa S; Ragno R; Esté JA; Botta M
J Chem Inf Model; 2006; 46(3):1344-51. PubMed ID: 16711753
[TBL] [Abstract][Full Text] [Related]
8. Multiple and multivalent interactions of novel anti-AIDS drug candidates, sulfated polymannuronate (SPMG)-derived oligosaccharides, with gp120 and their anti-HIV activities.
Liu H; Geng M; Xin X; Li F; Zhang Z; Li J; Ding J
Glycobiology; 2005 May; 15(5):501-10. PubMed ID: 15616125
[TBL] [Abstract][Full Text] [Related]
9. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
[TBL] [Abstract][Full Text] [Related]
10. Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.
Balzarini J; Van Laethem K; Hatse S; Froeyen M; Van Damme E; Bolmstedt A; Peumans W; De Clercq E; Schols D
Mol Pharmacol; 2005 May; 67(5):1556-65. PubMed ID: 15718224
[TBL] [Abstract][Full Text] [Related]
11. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.
Chiba H; Inokoshi J; Nakashima H; Omura S; Tanaka H
Biochem Biophys Res Commun; 2004 Mar; 316(1):203-10. PubMed ID: 15003531
[TBL] [Abstract][Full Text] [Related]
12. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
13. CD4 mimics targeting the mechanism of HIV entry.
Yamada Y; Ochiai C; Yoshimura K; Tanaka T; Ohashi N; Narumi T; Nomura W; Harada S; Matsushita S; Tamamura H
Bioorg Med Chem Lett; 2010 Jan; 20(1):354-8. PubMed ID: 19926478
[TBL] [Abstract][Full Text] [Related]
14. T cell-tropic HIV gp120 mediates CD4 and CD8 cell chemotaxis through CXCR4 independent of CD4: implications for HIV pathogenesis.
Iyengar S; Schwartz DH; Hildreth JE
J Immunol; 1999 May; 162(10):6263-7. PubMed ID: 10229873
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel anti-HIV active G-quadruplex-forming oligonucleotides.
Di Fabio G; D'Onofrio J; Chiapparelli M; Hoorelbeke B; Montesarchio D; Balzarini J; De Napoli L
Chem Commun (Camb); 2011 Feb; 47(8):2363-5. PubMed ID: 21305065
[TBL] [Abstract][Full Text] [Related]
16. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding.
Uttekar MM; Das T; Pawar RS; Bhandari B; Menon V; Nutan ; Gupta SK; Bhat SV
Eur J Med Chem; 2012 Oct; 56():368-74. PubMed ID: 22858223
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of neomycin, paromomycin, and neamine-arginine conjugates, targeting HIV-1 gp120-CXCR4 binding step.
Borkow G; Vijayabaskar V; Lara HH; Kalinkovich A; Lapidot A
Antiviral Res; 2003 Nov; 60(3):181-92. PubMed ID: 14638394
[TBL] [Abstract][Full Text] [Related]
19. The characteristic structure of anti-HIV actinohivin in complex with three HMTG D1 chains of HIV-gp120.
Zhang F; Hoque MM; Jiang J; Suzuki K; Tsunoda M; Takeda Y; Ito Y; Kawai G; Tanaka H; Takénaka A
Chembiochem; 2014 Dec; 15(18):2766-73. PubMed ID: 25403811
[TBL] [Abstract][Full Text] [Related]
20. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.
González-Ortega E; Mena MP; Permanyer M; Ballana E; Clotet B; Esté JA
Antimicrob Agents Chemother; 2010 Oct; 54(10):4487-92. PubMed ID: 20643898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
